An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma

Trial Profile

An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Arsenic trioxide (Primary)
  • Indications Basal cell cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 17 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top